IFNL2 Products By Gene Name

NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox"> NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." alt="IL-28A/IFN-lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND₅₀ is typically 0.3-1.5 µg/mL." class="big_lightbox"> 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND₅₀ is typically 0.3-1.5 µg/mL." class="big_thumb" />

MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994)." class="big_lightbox"> MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994)." class="big_thumb" />

1587-IL) was serially diluted and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15871) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 1587-IL) was serially diluted and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15871) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Mouse IL-28A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4635). The ND₅₀ is typically 3-15 µg/mL." class="big_lightbox"> 4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Mouse IL-28A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4635). The ND₅₀ is typically 3-15 µg/mL." alt="Recombinant Mouse IL-28A (Catalog # 4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Mouse IL-28A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4635). The ND₅₀ is typically 3-15 µg/mL." class="big_thumb" />

1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND₅₀ is typically 1-8 µg/mL." class="big_lightbox"> 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND₅₀ is typically 1-8 µg/mL." alt="Recombinant Human IL-28A/IFN-lambda 2 (Catalog # 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND₅₀ is typically 1-8 µg/mL." class="big_thumb" />

4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by Resazurin. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Mouse IL-28A Monoclonal Antibody (Catalog # MAB4635). The ND₅₀ is typically 2-10 µg/mL." class="big_lightbox"> 4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by Resazurin. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Mouse IL-28A Monoclonal Antibody (Catalog # MAB4635). The ND₅₀ is typically 2-10 µg/mL." alt="Recombinant Mouse IL-28A (Catalog # 4635-ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by Resazurin. Inhibition of EMCV activity elicited by Recombinant Mouse IL-28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Mouse IL-28A Monoclonal Antibody (Catalog # MAB4635). The ND₅₀ is typically 2-10 µg/mL." class="big_thumb" />

1587-IL) was serially diluted and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15871) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 1587-IL) was serially diluted and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15871) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" alt="Recombinant Human IL‑28A/IFN‑ lambda 2 (Catalog # 1587-IL) was serially diluted and captured by Mouse Anti-Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB15871) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />